ATE468351T1 - Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten - Google Patents

Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten

Info

Publication number
ATE468351T1
ATE468351T1 AT07703325T AT07703325T ATE468351T1 AT E468351 T1 ATE468351 T1 AT E468351T1 AT 07703325 T AT07703325 T AT 07703325T AT 07703325 T AT07703325 T AT 07703325T AT E468351 T1 ATE468351 T1 AT E468351T1
Authority
AT
Austria
Prior art keywords
specific antibodies
neutralizing
binding
peptide aptamer
diagnostic
Prior art date
Application number
AT07703325T
Other languages
English (en)
Inventor
Dominique Rigal
Julien Thibaut
Gemain Gillet
Yves Merieux
Original Assignee
Diagnostische Forsch Stiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostische Forsch Stiftung filed Critical Diagnostische Forsch Stiftung
Application granted granted Critical
Publication of ATE468351T1 publication Critical patent/ATE468351T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07703325T 2006-02-07 2007-02-07 Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten ATE468351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06002496 2006-02-07
PCT/EP2007/001042 WO2007090630A2 (en) 2006-02-07 2007-02-07 Peptide aptamer for neutralizing the binding of platelet antigene specific antibodies and diagnostic and therapeutic applications containing the same

Publications (1)

Publication Number Publication Date
ATE468351T1 true ATE468351T1 (de) 2010-06-15

Family

ID=38223347

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703325T ATE468351T1 (de) 2006-02-07 2007-02-07 Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten

Country Status (8)

Country Link
US (2) US8183055B2 (de)
EP (1) EP1987057B1 (de)
JP (1) JP5042237B2 (de)
AT (1) ATE468351T1 (de)
DE (1) DE602007006634D1 (de)
DK (1) DK1987057T3 (de)
ES (1) ES2345569T3 (de)
WO (1) WO2007090630A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0717166D0 (en) * 2007-09-04 2007-10-17 Univ Brighton Method for stabilisation of purified P-Glycoprotein
JP5210620B2 (ja) * 2007-12-19 2013-06-12 独立行政法人科学技術振興機構 ペプチドアプタマーライブラリーの作製方法および用途
EP2681304B1 (de) 2011-03-03 2020-05-27 The Regents of The University of California Verfahren zur strukturierung von zellen auf einem substrat
EP2796880B1 (de) * 2013-04-26 2016-10-26 Davos Diagnostics AG Typisierung von Blutplättchen-Alloantigenen und Blutplättchen-Antikörpertests
RS59704B1 (sr) 2014-03-31 2020-01-31 Univ I Tromsoe Norges Arktiske Univ Antitela protiv hpa-1a

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223390D0 (en) 1992-11-07 1992-12-23 Common Services Agency Anti-hpa1 testing

Also Published As

Publication number Publication date
WO2007090630A2 (en) 2007-08-16
WO2007090630A3 (en) 2007-09-20
US8183055B2 (en) 2012-05-22
DE602007006634D1 (de) 2010-07-01
JP5042237B2 (ja) 2012-10-03
US8563704B2 (en) 2013-10-22
EP1987057B1 (de) 2010-05-19
US20120245338A1 (en) 2012-09-27
DK1987057T3 (da) 2010-08-30
EP1987057A2 (de) 2008-11-05
JP2009525725A (ja) 2009-07-16
US20090318363A1 (en) 2009-12-24
ES2345569T3 (es) 2010-09-27

Similar Documents

Publication Publication Date Title
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CL2016002624A1 (es) Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011)
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA201100527A1 (ru) Биологические продукты
MX344935B (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
TR201818881T4 (tr) Sinyal Amplifikasyonu İmmünodeneyleri
EP3255063A3 (de) Antikörper gegen matrix-metalloproteinase-9
ATE550354T1 (de) Humane ringspezifische bnp-antikörper
BRPI0114343B1 (pt) MÉTODO PARA DETECÇÃO DE IMUNOGLOBULINA IgE E PARA DIAGNÓSTICO IN VITRO DE ALERGIAS, BEM COMO CHIP DE MICROARRANJO E KIT QUE O COMPREENDE
BRPI0511448A (pt) anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
IN2014DN08011A (de)
ATE468351T1 (de) Peptidaptamer zum neutralisieren der bindung von platelet-antigen-spezifischen antikörpern und diagnostische und therapeutische anwendungen, die dieses enthalten
JP2016528236A5 (de)
ATE474857T1 (de) Antikörper gegen ein epitop auf agr2, assays und hybridome
EP2565647A4 (de) Reagens zum testen eines antikörpers gegen treponema pallidum
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
DE502006004301D1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
RU2012127077A (ru) Методика проведения иммунохроматографического анализа для серодиагностики
ATE443871T1 (de) Test zum nachweis von pathologischen prionen
RU2010134106A (ru) Способ лабораторной диагностики клещевого риккетсиоза с использованием иммуноферментного анализа для определения антител к антигену rickettsia sibirica
DE60122306D1 (de) Antikörper, die spezifisch für freies inaktives psa sind, und ihre verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties